To determine whether targeting PDGFR holds potential as a therapeutic approach for CCA, our study examined the expression of PDGF and PDGFR in OV-related CCA patient tissues, as well as the anti-tumor effects of CP-673451. The gene discussed is PDGFRB; the disease is cholangiocarcinoma.